Literature DB >> 9445240

Parathyroid carcinoma.

A C Cordeiro1, F L Montenegro, M A Kulcsar, L A Dellanegra, M R Tavares, P Michaluart, A R Ferraz.   

Abstract

BACKGROUND: Parathyroid carcinoma is rare and represents 0.1% to 5% of the cases of hyperparathyroidism. New accounts are important to the understanding of these tumors. Experience in 9 cases is reported.
METHODS: From 1970 to 1995, 10 patients with parathyroid carcinoma demonstrated by clinical course or pathologic features of malignancy were treated. The patient's clinical data, laboratory and imaging examinations, surgical findings, pathology, recurrences, and survival were analyzed.
RESULTS: One male patient was excluded because of insufficient data. Average age was 51 years, with female:male ratio of 2:1. Average calcium level was 14,3 mg/dL. Palpable mass was found in 55%, bone disease in 89%, and renal disease in 78%. Four patients were reoperations. Five were operated on for hyperparathyroidism (1/tertiary). Capsular invasion was the most incident pathologic feature. Local recurrence occurred in 55%; neck node and bone metastasis in 11%, and lung in 33%. Two patients are alive and 5 died of disease.
CONCLUSIONS: Parathyroid carcinoma has clinical and laboratory features that can help diagnosis at the first surgery. It seems to have variable malignancy.

Entities:  

Mesh:

Year:  1998        PMID: 9445240     DOI: 10.1016/s0002-9610(97)00228-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Lymph node involvement and surgical approach in parathyroid cancer.

Authors:  Klaus-Martin Schulte; Nadia Talat; John Miell; Caje Moniz; Prakash Sinha; Salvador Diaz-Cano
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

2.  Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.

Authors:  Yasuhiro Takeuchi; Shunsuke Takahashi; Daishu Miura; Makoto Katagiri; Noriaki Nakashima; Hiroko Ohishi; Ryutaro Shimazaki; Yoshihiro Tominaga
Journal:  J Bone Miner Metab       Date:  2016-11-21       Impact factor: 2.626

3.  Differential findings of tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism.

Authors:  Miju Cheon; Joon Young Choi; Jae-Hoon Chung; Ji Young Lee; Sook Kyung Cho; Jang Yoo; Soo Bin Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-08-19

Review 4.  Nonfunctional parathyroid carcinoma.

Authors:  G A Giessler; D J Beech
Journal:  J Natl Med Assoc       Date:  2001 Jul-Aug       Impact factor: 1.798

5.  [Lymphadenectomy for thyroid and lymph node carcinomas].

Authors:  O Gimm; H Dralle
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

6.  Parathyroid carcinoma: the importance of high clinical suspicion for a correct management.

Authors:  Gabriele Ricci; Marco Assenza; Marco Barreca; Gianluca Liotta; Livio Paganelli; Angelo Serao; Giovanni Tufodandria; Pierluigi Marini
Journal:  Int J Surg Oncol       Date:  2012-09-19

Review 7.  Total parathyroidectomy in a large cohort of cases with hyperparathyroidism associated with multiple endocrine neoplasia type 1: experience from a single academic center.

Authors:  Fabio Luiz de Menezes Montenegro; Delmar Muniz Lourenço; Marcos Roberto Tavares; Sergio Samir Arap; Climerio Pereira Nascimento; Ledo Mazzei Massoni Neto; André D'Alessandro; Rodrigo Almeida Toledo; Flávia Lima Coutinho; Lenine Garcia Brandão; Gilberto de Britto e Silva Filho; Anói Castro Cordeiro; Sergio Pereira Almeida Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

8.  Parathyroid surgery during the COVID-19 pandemic: Time to think about the "New Normal".

Authors:  Fábio Luiz de Menezes Montenegro; Marília D'Elboux Guimarães Brescia; Sergio Samir Arap; Marco Aurélio Valmondes Kulcsar; Marcos Roberto Tavares; Luiz Paulo Kowalski
Journal:  Clinics (Sao Paulo)       Date:  2020       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.